Literature DB >> 6245983

Use of a common standard for comparison of insulin C-peptide measurements by different laboratories.

C P Caygill, R E Gaines Das, D R Bangham.   

Abstract

A synthetic human C-peptide analogue has been used as a common standard for the comparison of insulin C-peptide measurements in seven assay systems in six laboratories. Even in terms of this common standard there was statistically significant numerical heterogeneity between laboratories for estimates of the C-peptide content of the same plasma samples. However, the consistency in ranking order of estimates of C-peptide in the plasma samples between laboratories suggests that laboratories are in most cases measuring at least similar immunoreactive constituents and that a reference plasma might prove useful in comparing results between laboratories. Until a more suitable reference material is available, the synthetic analogue, 64 formyllysine C-peptide, in ampoules coded 76/561, will be made available for research purposes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245983     DOI: 10.1007/bf00251916

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  Human C-peptide in normal and diabetic subjects.

Authors:  L G Heding; S M Rasmussen
Journal:  Diabetologia       Date:  1975-06       Impact factor: 10.122

2.  Standardization in peptide hormone immunoassays: principle and practice.

Authors:  D R Bangham
Journal:  Clin Chem       Date:  1976-07       Impact factor: 8.327

3.  Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.

Authors:  D L Horwitz; J I Starr; M E Mako; W G Blackard; A H Rubenstein
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

4.  Detection of peptidase activity in albumin preparations.

Authors:  C P Caygill
Journal:  Clin Chim Acta       Date:  1977-08-01       Impact factor: 3.786

5.  Circulating C-peptide immunoreactivity. Studies in normals and diabetic patients.

Authors:  M B Block; M E Mako; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1972-10       Impact factor: 9.461

6.  Heterogeneity of circulating C-peptide.

Authors:  H Kuzuya; P M Blix; D L Horwitz; A H Rubenstein; D F Steiner; C Binder; O K Faber
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

7.  Estimation and correction of bias in potency estimates from radioimmunoassays by use of a reference material.

Authors:  R E Das
Journal:  J Biol Stand       Date:  1978-10

8.  Calibration of replacement standards for radioimmunoassay: a method for comparison of dose-response curves given by several preparations in a single assay [proceedings].

Authors:  R E Gaines Das; P M Cotes
Journal:  J Endocrinol       Date:  1978-05       Impact factor: 4.286

9.  Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects.

Authors:  M Perley; D M Kipnis
Journal:  Diabetes       Date:  1966-12       Impact factor: 9.461

10.  Human C-peptide immunoreactivity (CPR) in blood and urine - evaluation of a radioimmunoassay method and its clinical applications.

Authors:  T Kuzuya; T Saito; S Yoshida; A Matsuda
Journal:  Diabetologia       Date:  1976-10       Impact factor: 10.122

  10 in total
  4 in total

1.  Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes.

Authors:  S Madsbad
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

Review 2.  Insulin antibody determination: theoretical and practical considerations.

Authors:  W G Reeves
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

3.  Basal and 24-h C-peptide and insulin secretion rate in normal man.

Authors:  Y T Kruszynska; P D Home; I Hanning; K G Alberti
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

4.  C-peptide antibodies induced by bovine insulin therapy.

Authors:  W G Reeves; C A Douglas
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.